We are live on ! Find out more
CVRS

CORINDUS VASCULAR ROBOTICS, INC
CVRS

Delisted

CVRS was delisted on the 28th of October, 2019.

54 hedge funds and large institutions have $123M invested in CORINDUS VASCULAR ROBOTICS, INC in 2017 Q2 according to their latest regulatory filings, with 10 funds opening new positions, 26 increasing their positions, 8 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

225% more repeat investments, than reductions

Existing positions increased: 26 | Existing positions reduced: 8

67% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 6

47% more capital invested

Capital invested by funds: $83.5M → $123M (+$39.1M)

8% more funds holding

Funds holding: 5054 (+4)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

Holders
54
Holders Change
+4
Holders Change %
+8%
% of All Funds
1.35%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.02%
New
10
Increased
26
Reduced
8
Closed
6
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
HM
1
HealthCor Management
New York
$37.2M
CCM
2
Consonance Capital Management
New York
$28.1M
HEC
3
Hudson Executive Capital
New York
$21.1M
Fidelity Investments
4
Fidelity Investments
Massachusetts
$11.7M
BlackRock
5
BlackRock
New York
$6.95M +$1.88M +1,413,313 +61%
Vanguard Group
6
Vanguard Group
Pennsylvania
$6.1M +$1.6M +1,198,384 +58%
Northern Trust
7
Northern Trust
Illinois
$1.79M +$381K +285,811 +42%
State Street
8
State Street
Massachusetts
$1.72M +$379K +284,507 +44%
Geode Capital Management
9
Geode Capital Management
Massachusetts
$1.35M +$72.6K +54,463 +8%
Wellington Management Group
10
Wellington Management Group
Massachusetts
$1.31M -$288K -216,291 -23%
BCM
11
Bridgeway Capital Management
Texas
$931K +$146K +109,883 +28%
Charles Schwab
12
Charles Schwab
California
$532K
Bank of New York Mellon
13
Bank of New York Mellon
New York
$426K +$88.4K +66,368 +41%
TCIM
14
TIAA CREF Investment Management
New York
$419K +$128K +96,156 +74%
US Bancorp
15
US Bancorp
Minnesota
$374K
TA
16
Teachers Advisors
New York
$312K +$145K +108,745 +185%
California State Teachers Retirement System (CalSTRS)
17
California State Teachers Retirement System (CalSTRS)
California
$276K +$50.6K +38,000 +34%
UBS Group
18
UBS Group
Switzerland
$246K +$121K +91,083 +221%
Deutsche Bank
19
Deutsche Bank
Germany
$221K +$110K +82,866 +226%
New York State Common Retirement Fund
20
New York State Common Retirement Fund
New York
$166K +$91.4K +68,599 +335%
RhumbLine Advisers
21
RhumbLine Advisers
Massachusetts
$150K +$43.4K +32,608 +68%
Morgan Stanley
22
Morgan Stanley
New York
$145K -$558K -419,157 -84%
Goldman Sachs
23
Goldman Sachs
New York
$109K +$46.7K +35,086 +148%
AIG
24
American International Group
New York
$97K +$24.2K +18,195 +54%
VOYA Investment Management
25
VOYA Investment Management
Georgia
$97K +$69.6K +52,256 New

CVRS Hedge Fund Activity: Q2 2017 in Review

54 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in CORINDUS VASCULAR ROBOTICS, INC (CVRS) for Q2 2017, worth a combined $123M — up 47% from $83.5M a quarter earlier.

Buyers outnumbered sellers: 10 funds opened new CVRS positions and 6 closed out — a net gain of 4 holders — while 26 added to existing stakes and 8 trimmed.

The largest buyer was BlackRock, adding an estimated $1.88M. The largest seller was Laurion Capital Management, exiting entirely with an estimated $1.06M sold.

  • 54 institutional investors held CORINDUS VASCULAR ROBOTICS, INC (CVRS) as of Q2 2017, up from 50 in Q1 2017.
  • Funds reported $123M of CORINDUS VASCULAR ROBOTICS, INC stock for Q2 2017, up 47% quarter-over-quarter.
  • 10 funds opened new CORINDUS VASCULAR ROBOTICS, INC positions in Q2 2017 and 6 closed out, a net change of +4 holders.
  • The largest CORINDUS VASCULAR ROBOTICS, INC buyer in Q2 2017 was BlackRock, an estimated $1.88M added.
  • The largest CORINDUS VASCULAR ROBOTICS, INC seller in Q2 2017 was Laurion Capital Management, an estimated $1.06M sold.

Based on aggregated 13F filings for Q2 2017.